Cargando…

Cerebral venous sinus thrombosis following ChAdOx1 nCoV-19 AstraZeneca COVID-19 vaccine

A woman in her mid-twenties was admitted with headache, ultimately leading to a diagnosis of cerebral venous sinus thrombosis 10 days after receiving a first dose of the AstraZeneca ChAdOx1 nCoV-19 vaccine (Vaxzevria). We report this case from clinical investigations to outcomes and discuss the issu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Shyam S, Gulli, Giosue, Sharma, Pankaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107960/ https://www.ncbi.nlm.nih.gov/pubmed/37077469 http://dx.doi.org/10.1177/20480040231169464

Ejemplares similares

Acute Arterial Occlusion Following ChAdOx1 nCov-19 (Oxford–AstraZeneca) Vaccination
por: Ali, Azhar, et al.
Publicado: (2022)

Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca)
por: Lee, Hyo Jin, et al.
Publicado: (2023)

Systemic capillary leak syndrome after ChAdOx1 nCOV-19 (Oxford–AstraZeneca) vaccination
por: Robichaud, Julie, et al.
Publicado: (2021)

Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine
por: Clayton-Chubb, Daniel, et al.
Publicado: (2021)

Bilateral adrenal haemorrhage with renal infarction after ChAdOx1 nCoV-19 AstraZeneca vaccination
por: Tha, Tun, et al.
Publicado: (2022)

To what extent AstraZeneca ChAdOx1 nCoV-19 vaccine is safe and effective? Rapid systematic review
por: Mohamed Hussein, Aliae A. R., et al.
Publicado: (2022)

Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
por: Teh, Natalie, et al.
Publicado: (2021)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
por: Mikołajczyk, Marek, et al.
Publicado: (2022)

Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination
por: Waraich, Ammar, et al.
Publicado: (2021)

Vaccine‐induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine–A case report
por: Al Rawahi, Bader, et al.
Publicado: (2021)

Parsonage-Turner Syndrome Following Covishield (AstraZeneca ChAdOx1 nCoV-19) Vaccination: A Case Report
por: Lakkireddy, Maheshwar, et al.
Publicado: (2022)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
por: Ali, Syed B., et al.
Publicado: (2022)

Syndrome de fuite capillaire systémique après l’administration du vaccin ChAdOx1 nCOV-19 (Oxford–AstraZeneca)
por: Robichaud, Julie, et al.
Publicado: (2021)

Anti-GBM Disease after Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccination: A Report of Two Cases
por: Coorey, Craig Peter, et al.
Publicado: (2022)

Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Varona, Jose F., et al.
Publicado: (2021)

Superficial Thrombophlebitis of the Penis following AstraZeneca ChAdOx1-S Vaccination: A Rare Venous Thromboembolic Complication
por: Winston, Joshua, et al.
Publicado: (2022)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023)

Limb ischemia and pulmonary artery thrombosis after the ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine: a case of vaccine-induced immune thrombotic thrombocytopenia
por: Jones, Melissa, et al.
Publicado: (2021)

Acute small fiber neuropathy after Oxford‐AstraZeneca ChAdOx1‐S vaccination: A report of three cases and review of the literature
por: Abbott, Molly G., et al.
Publicado: (2022)

Case Report of Serum Sickness-like Reaction following the First Dose of the Chimpanzee Adenovirus-Vectored AstraZeneca COVID-19 Vaccine, ChAdOx1
por: Alzaidi, Areej Awad, et al.
Publicado: (2023)

Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia
por: Gordon, Sally F., et al.
Publicado: (2021)

Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for people < 60 years in Australia
por: MacIntyre, Chandini Raina, et al.
Publicado: (2021)

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
por: Pottegård, Anton, et al.
Publicado: (2021)

The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
por: Tran, Huyen, et al.
Publicado: (2022)

Pregnant and Breastfeeding Mothers Who Have Received the ChAdOx1 AstraZeneca COVID-19 Vaccine May Have Infants with an Increased Risk of Zinc Insufficiency and SCID Disease
por: Ahmed, Amr, et al.
Publicado: (2023)

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19()
por: Morales Varas, G., et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021)

Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Oxford–AstraZeneca COVID-19 vaccine efficacy
por: Knoll, Maria Deloria, et al.
Publicado: (2021)

AstraZeneca COVID-19 vaccine-related thromboembolism
Publicado: (2021)

Bleeding and clotting with AstraZeneca's COVID-19 vaccine
Publicado: (2021)

Cerebral venous sinus thrombosis secondary to ChAdOx-1 nCov-19 vaccine
por: Atta, Syed Noman, et al.
Publicado: (2021)

COVID-19 outbreak response at a nursing hospital in South Korea in the post-vaccination era, including an estimation of the effectiveness of the first shot of the Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1-S)
por: Kim, Chanhee, et al.
Publicado: (2022)

Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine
por: Lineburg, Katie E, et al.
Publicado: (2021)

Postvaccinal Encephalitis after ChAdOx1 nCov‐19
por: Zuhorn, Frédéric, et al.
Publicado: (2021)

AstraZeneca COVID-19 vaccine: no increased rate of VTE
Publicado: (2021)

No increased risk of anaphylaxis with AstraZeneca COVID-19 vaccine
Publicado: (2021)

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
por: Agharbi, F.-Z., et al.
Publicado: (2022)

AstraZeneca COVID-19 vaccine-related thrombocytopenia and thrombosis
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mukcqd4du9j9jvfg6vcfc466l6